We describe a young woman with multiple endocrine neoplasia-1 (MEN-1) who presented with severe nausea as a result of hyperparathyroidism (HPT). We present a case report, review the relevant literature in regards to physiology, and offer a target source for symptom control.
iNTRoDuCTioN
Gastrointestinal manifestations of hyperparathyroidism (HPT) have been noted since the earliest description of the disease in the early 1900s. 1, 2 The most commonly associated symptoms include constipation, heartburn, nausea and loss of appetite. Nausea, specifically, has been described in up to 25% of patients with HPT. 2, 3 Nausea and resultant emeses can be quite debilitating, and may even mimic hyperemesis gravidum in pregnancy. 4, 5 The physiologic mechanism of nausea in HPT is not fully understood.
wjoes

CASE REPoRT
A 19-year old woman who was part of a multiple endocrine neoplasia type 1 (MEN-1) kindred family and with known menin protein mutation presented to our clinic is a 19-year-old woman with a known menin protein mutation and is part of a multiple endocrine neoplasia type 1 (MEN-1) kindred family. Postoperatively, she developed severe and persistent nausea. At 4 and 6 weeks, computed tomography (CT) scans of her abdomen and pelvis showed no abnormalities or fluid collections. Six weeks postoperatively, her serum calcium level was 11.6 mg/dl and PTH was 78 pg/ml. A trial of cinacalcet was given and her nausea immediately resolved. A sestamibi localization scan revealed parathyroid hyperplasia (Fig. 2) . She underwent subtotal parathyroidectomy (Fig. 3) shortly thereafter and has been asymptomatic at 3 months follow-up.
DiSCuSSioN
The physiologic mechanisms behind gastrointestinal symptomatology of HPT have not been fully elucidated. Whether the primary culprit is PTH itself or the resul tant hypercalcemia has yet to be definitively proven. Pre sence of symptoms with concurrent elevations of both molecules makes delineation difficult. In the late 1960s, there was some speculation that sustained PTH levels may affect gene expression resulting in altered gastric mucus and ensuing destruction of gastric mucosa. 6 This was shown in some animal models in vivo, however was not reproducible in humans. 6 The ultimate downstream effect of mucosal damage is peptic ulcer disease (PUD), which has been associated with hyperparathyroid states in historical studies. [6] [7] [8] [9] Although the major symptom of PUD is abdominal pain, nausea can occur as well. Hypercalcemia (both within and outside the setting of HPT) has been associated with a number of gastrointestinal manifestations including anorexia, nausea, abdominal pain, and constipation. 10 Nausea and hypercalcemia have been linked to gastrointestinal atony. 1, [7] [8] [9] The specific mechanism involves two concurrent processes. First, increased levels of calcium impede transmission of afferent stimuli and diminish efferent discharges due to constant amounts of acetylcholine in the sympathetic ganglia of the gut. In addition, a high calcium ion concentration at the neuromuscular junction of these ganglia alters the membrane potential and leads to reduced neuromuscular excitability. Collectively, this translates into decreased gastrointestinal tone. 1, 2, [7] [8] [9] When this occurs at the level of the stomach, nausea and emesis can occur.
Regardless of the specific molecular etiology of nausea, parathyroidectomy for HPT has been proven to reduce subjective symptomatology and improve quality of life for patients. 11 Resolution of general gastrointestinal symptoms, such as nausea have been reported to occur as early as 1 week after parathyroidectomy, although most patients demonstrate peak improvement at 6 weeks. 12 Our patient experienced subjective improvement of nausea both when she was on cinacalcet and after parathyroidectomy. Her symptoms were associated with an elevated calcium level, however due to the use of a calcimimetic (which reduces both PTH and calcium); it is difficult to know whether the primary driver was PTH or calcium. However, as previously mentioned, hypercalcemia is the end-result of elevated PTH and calcium inhibits sympathetic enteric ganglia. Therefore, at the present time, calcium should be considered the primary culprit. Therapies for symptom reduction should target hypercalcemia. Further molecular studies are needed to identify specific gastrointestinal physiologic pathways affected by PTH.
